Sucralfate therapy in NSAID bleeding gastropathy

Clinical Gastroenterology and Hepatology

Volumn 1, Issue 1, 2003, Pages 51-56

  Malagelada, Juan R ^a,i   Rodríguez de La Serna, Arturo ^b   Dammann, Hans Gert ^c   Pons, Miquel ^d   Armas, Carlos ^e   Sala, Miquel ^f   Tena, Xavier ^g   Celdrán, Enrique ^h   Mesa, Antoni ^h  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c Wissenschaftliches Institut   (Germany)

^d Hospital Municipal de Badalona   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^f HOSPITAL DE FIGUERES   (Spain)

^g Germans Trias i Pujol ^*  (Spain)

^h Biomedical Research Laboratory   (Spain)

ⁱ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; SUCRALFATE;

ARTICLE; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENDOSCOPY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OCCULT BLOOD; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; STOMACH EROSION; STOMACH HEMORRHAGE; STOMACH MUCOSA INJURY; SUSPENSION; SYMPTOM;

EID: 0141989847     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1053/jcgh.2003.50008     Document Type: Article

References (45)

1. García Rodríguez LA, Murray FE, Hawkey CJ, Yeomans ND. NSAID-associated ulcers: new directions in research and clinical management. Oxford: Oxford Clinical Communications, 1996.
2. Committee of Safety of Medicines. Non-steroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions. BMJ (Clin Res Ed) 1986;292:1190-1191.
3. Fries JR, Miller SR, Spitz PW, Williams CA, Hubert HB, Bloch DA. Towards an epidemiology of gastropathy associated with NSAIDs drug use. Gastroenterology 1989;96(suppl):649-655.
4. Hazleman BL. Incidence of gastropathy in destructive arthropathies. Scand J Rheumatol 1989;78(suppl):1-4.
5. Castleden CM, Pickles H. Suspected adverse drug reactions in elderly patients reported to the Committee of Safety of Medicines. Br J Clin Pharmacol 1988;26:347-353.
6. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991;114:257-263.
7. Larkai EN, Smith JL, Lisdky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic non-steroidal anti-inflammatory drug use. Am J Gastroenterol 1987;82:1153-1158.
8. Mellem H, Stave R, Myren J, Osnes M, Hanssen LE, Mosvold J, Hebnes KL. Symptoms in patients with peptic ulcer and haematemesis and/or melaena related to the use of NSAIDs. Scand J Gastroenterol 1985;82:1153-1158.
9. Abramson SB, Weissmann G. The mechanism of action of nonsteroidal anti-inflammatory drugs. Arthritis Rheum 1989;32:1-9.
10. Armstrong CP, Blower AL. NSAIDs and life-threatening complications of peptic ulceration. Gut 1987;28:527-532.
11. Kurata JH. An assessment of NSAIDs as a risk factor in ulcer diseases. Ann Intern Med 1991;114:311-317.
12. Lanza FL, Graham DY, Davies RE, Rack MF. Endoscopic comparison of cimetidine and sucralfate for prevention of naproxen-induced acute gastroduodenal injury. Effect of scoring method. Dig Dis Sci 1990;35:1494-1499.
13. Butt JH, Barthel JS, Moore RA. Clinical spectrum of upper gastrointestinal effects of NSAIDs. Am J Med 1988;84(suppl 2A):514.
14. Bjilsma JWJ. Multicenter Group. Treatment of endoscopy negative NSAID-induced upper gastrointestinal symptoms with cimetidine: an international multicenter collaborative study. Aliment Pharmacol Ther 1988;25:75-83.
15. Hollander D. Gastrointestinal complications of NSAIDs: prophylactic and therapeutic strategies. Am J Med 1994;96:274-281.
16. Ligumsky M, Karmeli F, Rachmilewitz D. Sucralfate protection against gastrointestinal damage: possible role of prostanoids. Isr J Med Sci 1986;22:801-806.
17. Hollander D, Tarnawski A, Gergely H, Zipser RD. Sucralfate protection of the gastric mucosa against ethanol-induced injury: a prostaglandin mediated process. Scand J Gastroenterol 1984;19(suppl 101):97-102.
18. Nexo E, Poulsen SS. Does epidermal growth factor play a role in the action of sucralfate? Scand J Gastroenterol 1987;22(suppl 127):45-49.
19. Tarnawski A, Tanoue K, Santos AM, Sarfeh IJ. Cellular and molecular mechanisms of gastric ulcer healing. Is the quality of mucosal scar affected by treatment? Scand J Gastroenterol 1995;210(suppl):9-14.
20. Cohen MM, Bowdler R, Gervais P, Morris GP, Wang HR. Sucralfate protection of human gastric mucosa against acute ethanol injury. Gastroenterology 1989;92:292-298.
21. Kaya N, Boyunapa H, Kahraman H, Altintop L. Protective effects of sucralfate and omeprazole on gastric mucosal damage induced by ethanol in rats. Wien Klin Wochenschr 1998;110:96-100.
22. Tarnawski A, Hollander D, Krause WJ, Zipser RD, Stachura J, Gergely H. Does sucralfate affect the normal gastric mucosa? Histological, ultrastructural, and functional assessment in the rat. Gastroenterology 1986;90:893-905.
23. Wallence JL, Morris GP, Beck PL, Williamson TE, Gingras GR. Effect of sucralfate on gastric prostaglandin and leukotriene synthesis: relationship to protective actions. Can J Physiol Pharmacol 1988;66:666-670.
24. Wu WC, Semble EL, Castell DO, Caldwell JR, Roth SH, Heller MD, Marsh WH. Sucralfate therapy of nonsteroidal anti-inflammatory drug-induced gastritis (abstr). Gastroenterology 1985;88:1636.
25. Wu WC, Semble EL, Castell DO, Caldwell JR, Roth SH, Heller MD, Marsh WH. Chronic sucralfate therapy of nonsteroidal anti-inflammatory drug-induced gastritis: a multi-center trial (abstr). Gastroenterology 1986;90:1696.
26. Caldwell JR, Roth SH, Wu WC, Semble EL, Castell DO, Heller MD, Marsh WH. Sucralfate treatment of NSAID-induced gastrointestinal symptoms and mucosal damage. Am J Med 1987;83(Suppl 3B):74-82.
27. Agrawal NM, Aziz K. Prevention of gastrointestinal complications associated with nonsteroidal antiinflammatory drugs. J Rheumatol 1998;51(suppl):17-20.
28. Lichtenstein DR, Syngal S, Wolfe MM. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. The double-edged sword. Arthritis Rheum 1995;38:5-18.
29. Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 1993;105:1078-1088.
30. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal antiinflammatory drugs. Lancet 1994;343:769-772.
31. Laporte JR, Carne X, Vidal X, Moreno V, Juan J. Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Catalan Countries Study on Upper Gastrointestinal Bleeding. Lancet 1991;337:85-89.
32. McCarthy DM. Nonsteroidal antiinflammatory drugs - the clinical dilemmas. Scand J Gastroenterol 1992;27(suppl 192):9-16.
33. Fries JF, Williams CA, Bloch DA, Michel BA. Nonsteroidal antiinflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991;91:213-222.
34. Piper JM, Ray WA, Daugherty JR, Griffin MR. Costicosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991;114:735-740.
35. Yeomans ND, Tulassay Z, Juhász L, Rácz I, Howard JM, Van Rensburg CJ, Swannell AJ, Hawkey CJ. Comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998;338:719-726.
36. Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, Yeomans ND. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998;338:727-734.
37. Konturek SJ, Kwiecien N, Obtulowicz W, Kopp B, Olesky J. Double blind controlled study on the effect of sucralfate on gastric prostaglandin formation and microbleeding in normal and aspirin treated man. Gut 1986;27:1450-1456.
38. Tesler MA, Lim ES. Protection of gastric mucosa by sucralfate from aspirin-induced erosions. J Clin Gastroenterol 1981;3(suppl 2):175-179.
39. Stern Al, Ward F, Hartley G. Protective effect of sucralfate against aspirin-induced damage to the human gastric mucosa. Am J Med 1987;83(suppl 3B):83-85.
40. Shepherd HA, Fine D, Hillier K, Jewell R, Cox N. Effect of sucralfate and cimetidine on rheumatoid patients with active gastroduodenal lesions who are taking NSAID. A pilot study. Am J Med 1989;86:49-54.
41. Agrawal NM, Roth S, Graham DY, White RH, Germain B, Brown JA, Stromatt SC. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized, controlled trial. Ann Intern Med 1991;115:195-200.
42. Wroblewski M, Ostberg H. Ulcer disease among geriatric inpatients with positive faecal occult blood test and/or iron deficiency anemia. A prospective study. Scand J Gastroenterol 1990;25:489-495.
43. Caruso I, Bianchi Porro G. Gastroscopic evaluation of anti-inflammatory agents. BMJ 1980;280:75-78.
44. Olivero JJ, Graham DY. Gastric adaptation to NSAID drugs in man. Scand J Gastroentrol 1992;27(suppl 193):53-58.
45. Konturek JW, Dembinski A, Stoll R, Domschke W, Konturek SJ. Mucosal adaptation to aspirin-induced gastric damage in humans. Studies on blood flow, gastric mucosal flow, gastric mucosal growth, and neutrophil activation. Gut 1994;35:1197-1204.